https://m2.mtmt.hu/ hun 2026-09-21 13:43 JournalArticle 32104224 VALIDATED true 0 false 2026-09-11T08:30:16.975+0000 2023-07-24T02:58:03.739+0000 2021-07-16T06:26:33.836+0000 true 10062250 Molnár-Taga Márta /api/admin/10062250 Admin Molnár-Taga Márta (SE 4-es admin) true 10062250 2024-06-01T00:10:46.872+0000 2024-06-01T00:10:46.872+0000 2021-10-14T06:41:03.618+0000 true 10078148 Havas Petra /api/admin/10078148 Admin Havas Petra (OMIII admin4) true true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Szekeres, G. true true /api/journal/10030219 REVIEWED FRONTIERS IN PSYCHIATRY 1664-0640 1664-0640 true false 10030219 false 10030219 true 1664-0640 1664-0640 Journal FOREIGN 12 689143 689143 9 2021 Background: Suboptimal treatment response during anti-depressive treatment is fairly common with the first antidepressant (AD) choice, followed by switching to another agent in the majority of cases. However, the efficacy of this strategy over continuation of the original agent is less solidly documented in real-life studies. The aim of our present study was to ascertain the effects of switching to duloxetine following inadequate response to prior ADs on general illness severity, pain, and health-related quality of life in a large sample of major depressive disorder (MDD) and generalized anxiety disorder (GAD) patients in a prospective, real-world, multicenter, observational study. Methods: A total of 578 participants with MDD or GAD were enrolled in 58 outpatient sites in an 8-week, single-arm, open-label, flexible-dose trial with duloxetine. Severity of symptoms [with Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I)], severity of pain (with a Visual Analog Scale), satisfaction with current treatment, and health-related quality of life [with the three-level version of the EuroQol five-dimensional questionnaire (EQ-5D-3L)] measures were recorded at baseline and at follow-up visits 4 and 8 weeks after initiation of treatment. Data were analyzed using ANOVA and mixed linear models. Results: 565 patients completed the study and comprised the analyzed dataset. Results indicated that severity of illness significantly decreased over the 8 weeks of the study and already at 4 weeks in both patient groups. Overall quality of life and all of its subindicators also significantly improved in both patient groups and so did subjective experience of pain. Satisfaction with current treatment also significantly increased during the study period. Frequency of side effects was low. In both GAD and MDD groups, two patients dropped out of the study due to adverse effects, leading to treatment termination in four cases (0.7%). Conclusions: This 8-week, multicenter, flexible-dosing, single-arm, open-label, observational real-life study in MDD and GAD patients switched to duloxetine after inadequate response or low tolerability to other ADs showed a significant positive effect on all outcome measures, including a significant decrease in illness severity as well as significant overall symptomatic improvement, with good tolerability. © Copyright © 2021 Szekeres, Rozsa, Dome, Barsony and Gonda. true true 2021 true true true false true false GOLD 2026-09-11 true https://doi.org/10.3389/fpsyt.2021.689143 4 0 4 4 1 4 4 4 1 4 4 4 4 4 0 0 4 4 4 4 0 0 0 Folyóiratcikk Journal Article 24 4 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 1 1 1 1 2023 0 0 0 0 0 2024 0 1 1 1 1 2025 0 2 2 2 2 Q1 false false false false 2021-07-15T06:29:34.719+0000 Nyírő Gyula Országos Pszichiátriai és Addiktoló...; Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K); Személyiség- és Egészségpszichológiai Tanszék (KRE / BTK) 4 48 3 5 0 true Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 96829056 /api/authorship/96829056 Szekeres, G. [Szekeres, György (Pszichiátria), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 1 0.2 true false false Author 10037064 /api/author/10037064 Szekeres György (Pszichiátria) Szekeres György true 10037064 true Szekeres G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96829057 /api/authorship/96829057 Rozsa, S. [Rózsa, Sándor (Pszichológia), szerző] Személyiség- és Egészségpszichológiai Tanszék (KRE / BTK) 2 0.2 false false false Author 10023354 /api/author/10023354 Rózsa Sándor (Pszichológia) Rózsa Sándor true 10023354 true Rozsa S. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96829058 /api/authorship/96829058 Dome, P. [Döme, Péter (pszichiátria), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K); Nyírő Gyula Országos Pszichiátriai és Addiktoló... 3 0.2 false false false Author 10023468 /api/author/10023468 Döme Péter (pszichiátria) Döme Péter true 10023468 true Dome P. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96829059 /api/authorship/96829059 Barsony, G. 4 0.2 false false false Barsony G. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 96829060 /api/authorship/96829060 Gonda, X. ✉ [Gonda, Xénia (Pszichiátria, psz...), szerző] Pszichiátriai és Pszichoterápiás Klinika (SE / AOK / K) 5 0.2 false true true Author 10003491 /api/author/10003491 Gonda Xénia (Pszichiátria, pszichiátriai genetika, farmakológia, pszichofarmakológia, pszichoterápia, klinikai pszichológia, pszichológia) Gonda Xénia true 10003491 true Gonda X. true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 19017569 /api/publicationidentifier/19017569 DOI: 10.3389/fpsyt.2021.689143 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.3389/fpsyt.2021.689143 https://doi.org/10.3389/fpsyt.2021.689143 false true PublicationIdentifier 19017570 /api/publicationidentifier/19017570 WoS: 000668642800001 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000668642800001 https://www.webofscience.com/wos/woscc/full-record/000668642800001 false true PublicationIdentifier 19017568 /api/publicationidentifier/19017568 Scopus: 85109046546 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85109046546 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85109046546 false true PublicationIdentifier 19017575 /api/publicationidentifier/19017575 PubMed: 34220591 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 34220591 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34220591&dopt=Abstract false true Keyword 17839 /api/keyword/17839 health-related quality of life true 17839 true Keyword 1068344 /api/keyword/1068344 generalized anxiety disorder true 1068344 true Keyword 1069715 /api/keyword/1069715 MAJOR DEPRESSIVE DISORDER true 1069715 true Keyword 1160083 /api/keyword/1160083 duloxetine true 1160083 true Keyword 1498213 /api/keyword/1498213 Clinical Global Impression scale true true SjrRating 11233510 /api/sjrrating/11233510 sjr:Q1 (2021) Scopus - Psychiatry and Mental Health FRONTIERS IN PSYCHIATRY 1664-0640 1664-0640 90 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 2738 /api/classificationexternal/2738 Scopus - Psychiatry and Mental Health true 2738 true Q1 DIRECT true true Reference 21774998 /api/reference/21774998 1. Detke, M.J., Lu, Y., Goldstein, D.J., McNamara, R.K., Demitrack, M.A., Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression (2002) J Psychiatr Res, 36, pp. 383-390. , 12393307 1 false true Reference 21774997 /api/reference/21774997 2. Detke, M.J., Lu, Y., Goldstein, D.J., Hayes, J.R., Demitrack, M.A., Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial (2002) J Clin Psychiatry, 63, pp. 308-315. , 12000204 2 false true Reference 21774996 /api/reference/21774996 3. Hudson, J.I., Perahia, D.G., Gilaberte, I., Wang, F., Watkin, J.G., Detke, M.J., Duloxetine in the treatment of major depressive disorder: an open-label study (2007) BMC Psychiatry, 7, p. 43. , 9248869 3 false true Reference 21774995 /api/reference/21774995 4. Barbosa, C.D., Balp, M.M., Kulich, K., Germain, N., Rofail, D., A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence (2012) Patient Prefer Adherence, 6, pp. 39-48. , 22272068 4 false true Reference 21774994 /api/reference/21774994 5. Goldstein, D.J., Lu, Y., Detke, M.J., Hudson, J., Iyengar, S., Demitrack, M.A., Effects of duloxetine on painful physical symptoms associated with depression (2004) Psychosomatics, 45, pp. 17-28. , 14709757 5 false true Reference 21774993 /api/reference/21774993 6. de Heer, E.W., Gerrits, M.M., Beekman, A.T., Dekker, J., van Marwijk, H.W., de Waal, M.W., The association of depression and anxiety with pain: a study from NESDA (2014) PLoS ONE, 9, p. e106907. , 25330004 6 false true Reference 21774992 /api/reference/21774992 7. Israel, J.A., The impact of residual symptoms in major depression (2010) Pharmaceuticals, 3, pp. 2426-2440. , 27713362 7 false true Reference 21774991 /api/reference/21774991 8. Jaracz, J., Gattner, K., Jaracz, K., Gorna, K., Unexplained painful physical symptoms in patients with major depressive disorder: prevalence, pathophysiology and management (2016) CNS Drugs, 30, pp. 293-304. , 27048351 8 false true Reference 21774990 /api/reference/21774990 9. Hoehn-Saric, R., McLeod, D.R., Zimmerli, W.D., Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms (1988) J Clin Psychiatry, 49, pp. 293-301. , 3045099 9 false true Reference 21774989 /api/reference/21774989 10. Cipriani, A., Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y., Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis (2018) Focus, 16, pp. 420-429. , 32021580 10 false true Reference 21774988 /api/reference/21774988 11. He, H., Xiang, Y., Gao, F., Bai, L., Gao, F., Fan, Y., Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: a network meta-analysis (2019) J Psychiatr Res, 118, pp. 21-30. , 31473564 11 false true Reference 21774987 /api/reference/21774987 12. Koponen, H., Allgulander, C., Erickson, J., Dunayevich, E., Pritchett, Y., Detke, M.J., Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians (2007) Prim Care Companion J Clin Psychiatr, 9, pp. 100-107. , 17607331 12 false true Reference 21774986 /api/reference/21774986 13. Rickels, K., Rynn, M., Iyengar, M., Duff, D., Remission of generalized anxiety disorder: a review of the paroxetine clinical trials database (2006) J Clin Psychiatry, 67, pp. 41-47. , 16426087 13 false true Reference 21774985 /api/reference/21774985 14. Nemeroff, C.B., Schatzberg, A.F., Goldstein, D.J., Detke, M.J., Mallinckrodt, C., Lu, Y., Duloxetine for the treatment of major depressive disorder (2002) Psychopharmacol Bull, 36, pp. 106-132 14 false true Reference 21774984 /api/reference/21774984 15. Furukawa, T.A., Kato, T., Shinagawa, Y., Miki, K., Fujita, H., Tsujino, N., Prediction of remission in pharmacotherapy of untreated major depression: development and validation of multivariable prediction models (2019) Psychol Med, 49, pp. 2405-2413. , 30430961 15 false true Reference 21774983 /api/reference/21774983 16. Yonkers, K.A., Warshaw, M.G., Massion, A.O., Keller, M.B., Phenomenology and course of generalised anxiety disorder (1996) Br J Psychiatry, 168, pp. 308-313. , 8833684 16 false true Reference 21774982 /api/reference/21774982 17. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice (2006) Am J Psychiatry, 163, pp. 28-40. , 16390886 17 false true Reference 21774981 /api/reference/21774981 18. Dolan, P., Modeling valuations for EuroQol health states (1997) Med Care, 35, pp. 1095-1108. , 9366889 18 false true Reference 21774980 /api/reference/21774980 19. DeLoach, L.J., Higgins, M.S., Caplan, A.B., Stiff, J.L., The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale (1998) Anesth Analg, 86, pp. 102-106. , 9428860 19 false true Reference 21774979 /api/reference/21774979 20. Guy, W., In: Guy W, editor (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 218-221. , Rockville, MD, National Institute for Mental Health, Clinical global impression., :, p 20 false true Reference 21774978 /api/reference/21774978 21. Milev, R.V., Giacobbe, P., Kennedy, S.H., Blumberger, D.M., Daskalakis, Z.J., Downar, J., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 4. neurostimulation treatments (2016) Can J Psychiatry, 61, pp. 561-575. , 27486154 21 false true Reference 21774977 /api/reference/21774977 22. Bauer, M., Severus, E., Moller, H.J., Young, A.H., Disorders, W., Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines (2017) Int J Psychiatry Clin Pract, 21, pp. 166-176. , 28367707 22 false true Reference 21774976 /api/reference/21774976 23. Ravindran, A.V., Balneaves, L.G., Faulkner, G., Ortiz, A., McIntosh, D., Morehouse, R.L., Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 5. Complementary and alternative medicine treatments (2016) Can J Psychiatry, 61, pp. 576-587. , 32015703 23 false true Reference 21774975 /api/reference/21774975 24. Bartova, L., Dold, M., Kautzky, A., Fabbri, C., Spies, M., Serretti, A., Results of the European group for the study of resistant depression (GSRD) - basis for further research and clinical practice (2019) World J Biol Psychiatry, 20, pp. 427-448. , 31340696 24 false true Reference 21774974 /api/reference/21774974 25. Nemeroff, C.B., Prevalence and management of treatment-resistant depression (2007) J Clin Psychiatry, pp. 17-25. , (,) 68(Sul 8 25 false true Reference 21774973 /api/reference/21774973 26. Hartford, J.T., Endicott, J., Kornstein, S.G., Allgulander, C., Wohlreich, M.M., Russell, J.M., Implications of pain in generalized anxiety disorder: efficacy of duloxetine (2008) Prim Care Companion J Clin Psychiatry, 10, pp. 197-204. , 18615176 26 false true Reference 21774972 /api/reference/21774972 27. Raouf, M., Glogowski, A.J., Bettinger, J.J., Fudin, J., Serotonin-norepinephrine reuptake inhibitors and the influence of binding affinity (2017) J Clin Pharm Ther, 42, pp. 513-517. , 28503727, (Ki) on analgesia 27 false true Reference 21774971 /api/reference/21774971 28. Muscatello, M.R.A., Zoccali, R.A., Pandolfo, G., Mangano, P., Lorusso, S., Cedro, C., Duloxetine in psychiatric disorders: expansions beyond major depression and generalized anxiety disorder (2019) Front Psychiatr, 10, p. 772. , 31749717 28 false true Reference 21774970 /api/reference/21774970 29. Knadler, M.P., Lobo, E., Chappell, J., Bergstrom, R., Duloxetine: clinical pharmacokinetics and drug interactions (2011) Clin Pharmacokinet, 50, pp. 281-294. , 21366359 29 false true Reference 21774969 /api/reference/21774969 30. Stahl, S.M., (2013) Stahl's Essential Psychopharmacology Neuroscientific Basis and Practical Application, , Cambridge, Cambridge University Press 30 false true Reference 21774968 /api/reference/21774968 31. Lunn, M.P., Hughes, R.A., Wiffen, P.J., Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia (2014) Cochrane Database Syst Rev, 3, p. Cd007115. , 24385423 31 false true /api/publication/32104224 Szekeres G. et al. A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder. (2021) FRONTIERS IN PSYCHIATRY 1664-0640 1664-0640 12<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10037064"><a href="/gui2/?type=authors&mode=browse&sel=10037064" target="_blank">Szekeres G. (<span class="authorship-author-name">Szekeres György</span> <span class="authorAux-mtmt"> Pszichiátria</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023354"><a href="/gui2/?type=authors&mode=browse&sel=10023354" target="_blank">Rozsa S. (<span class="authorship-author-name">Rózsa Sándor</span> <span class="authorAux-mtmt"> Pszichológia</span>) </a> </span> <span class="author-affil"><span title="Károli Gáspár Református Egyetem">KRE</span>/<span title="Bölcsészet- és Társadalomtudományi Kar">BTK</span>/<span title="Pszichológiai Intézet">Pszichológiai Intézet</span>/Személyiség- és Egészségpszichológiai Tanszék</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10023468"><a href="/gui2/?type=authors&mode=browse&sel=10023468" target="_blank">Dome P. (<span class="authorship-author-name">Döme Péter</span> <span class="authorAux-mtmt"> pszichiátria</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika; Nyírő Gyula Országos Pszichiátriai és Addiktológiai Intézet</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Barsony G. </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10003491"><a href="/gui2/?type=authors&mode=browse&sel=10003491" target="_blank">Gonda X. ✉ (<span class="authorship-author-name">Gonda Xénia</span> <span class="authorAux-mtmt"> Pszichiátria, pszichiátriai genetika, farmakoló...</span>) </a> </span> <span class="author-affil"><span title="Semmelweis Egyetem">SE</span>/<span title="Általános Orvostudományi Kar">AOK</span>/<span title="Klinikum">K</span>/Pszichiátriai és Pszichoterápiás Klinika</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32104224" target="_blank">A Real-World, Prospective, Multicenter, Single-Arm Observational Study of Duloxetine in Patients With Major Depressive Disorder or Generalized Anxiety Disorder</a></div> <div> <span class="journal-title">FRONTIERS IN PSYCHIATRY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/1664-0640">1664-0640</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1664-0640">1664-0640</a>)</span>: <span class="journal-volume">12</span> <span class="page"> Paper 689143. 9 p. </span> <span class="year">(2021)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.3389/fpsyt.2021.689143" target="_blank" href="https://doi.org/10.3389/fpsyt.2021.689143"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000668642800001" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000668642800001"> WoS </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85109046546" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85109046546"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="34220591" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34220591&dopt=Abstract"> PubMed </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Psychiatry and Mental Health&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 4</span> | Független: 4 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 4 | Scopus jelölt:&nbsp;1 | WoS/Scopus jelölt:&nbsp;4 | DOI jelölt:&nbsp;4 </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32104224</span> | <span class="status-data status-VALIDATED"> Egyeztetett </span> Forrás | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">Scopus</span> </div> <div class="lastModified">Utolsó módosítás: 2023.07.24. 04:58 Rózsa Sándor (Pszichológia) </div> </div></div>